News & Media

Press Releases

ADC Therapeutics Announces Final Close of Series E Financing Expansion

ADC Therapeutics Announces Final Close of Series E Financing Expansion
$103 million raised in Series E expansion, including a new U.S.-based institutional investor, brings total Series E proceeds to $303 million Lausanne, Switzerland, July 9, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced the final close of a $103 million

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019 Pivotal Phase II clinical trial of ADCT-301 in relapsed or refractory Hodgkin lymphoma expected to commence in coming months Lausanne, Switzerland, June 21, 2019 – ADC Therapeutics, an

ADC Therapeutics Announces Completion of a Series E Financing Expansion

ADC Therapeutics Announces Completion of a Series E Financing Expansion
Brings total raised in the Series E round to $276 million Lausanne, Switzerland, June 12, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced that it has closed a $76 million expansion of its Series E financing, bringing the total gross

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma
Three oral presentations and one poster presentation Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents and in combination therapies Lausanne, Switzerland, June 12, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced

ADC Therapeutics and Adagene Announce License Agreement

ADC Therapeutics and Adagene Announce License Agreement
ADC Therapeutics to develop next-generation masked antibody drug conjugates (ADCs), incorporating Adagene’s SAFEbody™ technology, with potential utility across multiple tumor types Collaboration enables focus on targets in which healthy tissue expression precludes development of ADCs incorporating traditional antibodies Lausanne, Switzerland and Suzhou, China, April 24, 2019 – ADC Therapeutics, an oncology drug discovery and development

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Combination trial to evaluate safety and anti-tumor activity of agents that target B-cell cancers Lausanne, Switzerland, February 20, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical trial

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
Combination of antibody drug conjugate and checkpoint inhibitor being evaluated for treatment of relapsed or refractory diffuse large B-cell, mantle cell and follicular lymphomas Lausanne, Switzerland, February 13, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors Lausanne, Switzerland, January 16, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical

ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors

ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors
Potential for new immune-oncology therapy using an antibody drug conjugate that targets regulatory T cells Lausanne, Switzerland, January 4, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase Ib clinical

ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors

ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors
Lausanne, Switzerland, January 3, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that Peter Hug, Ph.D., will be appointed to its board of directors. Dr. Hug is a 35-year veteran of Roche. Dr. Peter B. Corr, Chairman of the